Revolution Medicines and Iambic Announce $25M AI-Powered Drug Discovery Collaboration

Revolution Medicines and Iambic Therapeutics announced a multi-year technology and research collaboration in July 2025 to advance drug discovery using artificial intelligence123.

The partnership will utilize Iambic's AI-powered drug discovery platforms, including NeuralPLexer (for protein-ligand structure prediction) and PropANE (for property evaluation), trained on Revolution's proprietary oncology data12.

The collaboration specifically targets the discovery of new therapies for RAS-addicted cancers and other challenging oncology indications24.

Iambic will receive up to $25 million in a combination of upfront payments, milestone payments, and R&D funding as part of the deal12.

Both companies retain rights to pursue a set number of exclusive drug targets and can designate additional targets for independent development12.

The partnership aims to accelerate the discovery and development of innovative cancer therapies, addressing targets considered difficult by traditional approaches14.

Sources:

1. https://www.pharmafocuseurope.com/news/revolution-medicines-and-iambic-form-ai-driven-research

2. https://trial.medpath.com/news/5a0adb746b81fe25/revolution-medicines-partners-with-iambic-therapeutics-in-25m-ai-driven-drug-discovery-collaboration-for-ras-addicted-cancers

3. https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-and-iambic-announce-technology-and-research

4. https://www.ainvest.com/news/revolution-medicines-iambic-therapeutics-ai-powered-oncology-breakthroughs-drive-investment-upside-2507/